7/104 sources · 4 publishersUpdated Oct 31, 14:55 UTC
Oppenheimer upgrades Incyte to Outperform and raises price target to $144
Oppenheimer lifted Incyte’s rating from Perform to Outperform and increased its price target to $144 from $120. The upgrade follows Incyte’s third‑quarter 2026 report showing revenue of $1.56 billion, a 14% year‑over‑year increase and a beat of the $1.47 billion consensus. Non‑Jakafi products now represent more than 35% of total sales, and revenue has grown 25% over the past twelve months.
Why it matters
The higher price target implies roughly 23% upside from the recent close, according to Oppenheimer. The revenue beat and diversification beyond Jakafi support the upgraded outlook, potentially boosting investor sentiment.
Key facts
- 1Oppenheimer upgraded Incyte to Outperform from Perform and raised the price target to $144 from $120. investing.com
- 2Incyte reported third‑quarter 2026 revenue of $1.56 billion, surpassing the $1.47 billion forecast. investing.com
- 3Quarterly revenue was up 14% from the prior year. investing.com
- 4Products excluding Jakafi accounted for more than 35% of total product sales. investing.com
- 5Revenue grew 25% over the last twelve months. investing.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.